United States:
FTC Orphan Drug Pricing Investigations: What You Should Know
13 September 2017
Haug Partners
To print this article, all you need is to be registered or login on Mondaq.com.
Amanda Hamilton recently had her article "What Can the FTC
Do about Orphan Drug Prices?" published in the Antitrust
Health Care Chronicle for August 2017. Her article analyzes
what the FTC looks for when investigating orphan pharmaceutical
price claims.
Read the article
here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
